Industriebank Liof NV

NV Industriebank LIOF is the Limburg development and investment company. LIOF contributes to the prosperity of the province with an ongoing program to strengthen the province's economic base. LIOF targets industry and the dynamic service sector. Its four core activities are Acquisition, Participation, Development/Innovation and Business Parks, as these relate to the location/relocation of (foreign) companies, venture capital participation in Limburg companies with prospects, the development/implementation of programs and projects to sharpen the competitive edge of Limburg business and the coordination of the development of new business parks. LIOF has a strategic approach which targets opportunities for long-term economic development. In this it has a bridging role between government and business. LIOF is an ambitious professional organization and speaks the language that business understands.

Bart Joosten

Investment Professional

Patricia de Kort

Investment Manager Nedermaas Ventures

Kyra Manders

Investment Manager

Bert Roona

Investment Manager

Jeffrey Lutje Spelberg

Investment Manager

Ruud Verberne

Investment Manager

Krista van Weert

Investment Manager Participatiefonds

Gaby Zandbergen

Investment Manager Participatiefonds

17 past transactions

Embrosa

Seed Round in 2023
Developer of a social media marketing platform designed to make social media marketing easy and accessible for local entrepreneurs. The company's platform offers marketing tools with features like access to branded content, ready-made monthly Facebook planning, personal priority support, planning your posts to social media, and courses for beginners, thereby providing users with ready-made personal social planning.

Neuroplast

Series B in 2021
Neuroplast B.V., founded in 2013 and based in Geleen, the Netherlands, operates a stem cell manufacturing laboratory specializing in the development of low immunogenic stem cells. These innovative stem cells aim to provide therapeutic solutions for patients afflicted with neurodegenerative diseases. The company is positioned within the field of neuro-regenerative personalized medicine, which is recognized as a promising area of therapy requiring consistent standards and regulations to ensure effective treatment outcomes.

Neuroplast

Funding Round in 2020
Neuroplast B.V., founded in 2013 and based in Geleen, the Netherlands, operates a stem cell manufacturing laboratory specializing in the development of low immunogenic stem cells. These innovative stem cells aim to provide therapeutic solutions for patients afflicted with neurodegenerative diseases. The company is positioned within the field of neuro-regenerative personalized medicine, which is recognized as a promising area of therapy requiring consistent standards and regulations to ensure effective treatment outcomes.

Vacis

Venture Round in 2019
VACIS is the leading tissue engineering company for body-own blood vessels.VACIS develops in situ tissue engineered blood vessels providing novel therapeutic options for vascular surgery. Prosthetic vascular graft failure is a frequent complication in vascular surgery with substantial morbidity and health care costs. VACIS provides patients autologous graft vessels, with sustained patency and fewer complications requiring less corrective interventions.

Paztir

Series A in 2019
Paztir automates vehicle and box locks, tracks, and manages access, helping you save up to 30 minutes daily per vehicle, keeping your assets safe, and providing you with performance insights.

Grassa

Series A in 2019
Grassa B.V., founded in 2014 and headquartered in Venlo, Netherlands, specializes in upgrading grass and crops through a process known as bio refining. The company focuses on maximizing the value of plant materials by extracting proteins, fibers, and minerals from grass and vegetable waste to create high-quality animal feed and protein supplements. Utilizing a mobile refining machine, Grassa processes fresh grass from pastures, agricultural by-products, invasive aquatic plants from rivers, and natural grass from protected areas. The bio refining process results in four key products: fibers, protein, phosphate, and sap.

Phenospex

Series A in 2018
Phenospex BV develops a sensor platform and management system for daily and automated determination of plant growth dynamics. The company’s system enables crop management by analyzing plant parameters in combination with environmental and climate factors. Phenospex BV is based in Heerlen, the Netherlands.

Cristal Therapeutics

Venture Round in 2017
Cristal Therapeutics BV operates as a clinical stage pharmaceutical company. It develops nanomedicines based on its proprietary CriPec and CriPec ATN platform to treat diseases which include cancer. The company develops technology to transform drugs into nanoparticles. It also provides programs to develop nanomedicines for various therapeutic areas. The company was founded in 2011 and is based in Maastricht, the Netherlands.

Innosolids

Venture Round in 2015
Innosolids BV is a company based in Maastricht, Netherlands, specializing in the production and supply of color solutions for the plastics industry. It offers a diverse range of products, including pigments, masterbatch, liquid colors, compounds, and micro beads, as well as functional additives such as UV absorbers, heat stabilizers, antistatic products, flame retardants, nucleation agents, lubricants, and antioxidants. These products are utilized across various sectors, including sports and leisure, construction, automotive, and medical applications. Innosolids is positioned near the Brightland Campus, which enhances its technical capabilities and access to innovations in technology and chemistry. The company's experienced technical staff has a strong background in research and development, enabling it to effectively meet the needs of its clients in Europe and beyond.

Quality Circular Polymers

Funding Round in 2014
QCP provides brand owners and plastics convertors with polymers of high and consistent quality based on used plastics.

Ekompany

Venture Round in 2013
Ekompany International B.V., founded in 2010 and based in Born, the Netherlands, specializes in the development, manufacture, and marketing of coated mineral fertilizers for the horticulture and agriculture sectors. The company's product range caters to various agricultural needs, including crops such as maize, sugar beet, and potatoes, as well as horticultural varieties like tomatoes, peppers, and both soft and hard fruits. Ekompany also serves container nursery stocks, pot plants, and sports fields. The company operates a unique production facility that employs a patented, energy-efficient coating process, enabling the creation of advanced Controlled Release Fertilisers. These products have demonstrated their effectiveness in over 200 international field trials. Ekompany has sales operations in Western Europe and the Far East and has been a subsidiary of Kingenta Ecologic Engineering Group Co., Ltd. since early 2016.

Phenospex

Seed Round in 2011
Phenospex BV develops a sensor platform and management system for daily and automated determination of plant growth dynamics. The company’s system enables crop management by analyzing plant parameters in combination with environmental and climate factors. Phenospex BV is based in Heerlen, the Netherlands.

MagnaMedics

Series B in 2011
MagnaMedics engineers and produces magnetic nano- and microparticles that are used in medical devices, drug delivery tools and diagnostic kits. Diagnostic kits are used for determination of biomarkers in body fluids; the company focuses on proteomics and more specifically on high-quantity isolation of proteins as well as on research customers active in high-throughput screening of biomarkers.

FABPulous

Series A in 2010
FABPulous B.V. develops and markets diagnostic solutions for primary care and emergency medicine sectors. The company offers H-FABP True Rapid Test, a blood filtration device that detects a small protein found in capillary blood after a heart attack; and a test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP) to aid in the first-line diagnosis of acute myocardial infarction. It provides products through a network of distributors. The company was founded in 2008 and is based in Maastricht, the Netherlands.

TiGenix

Private Equity Round in 2009
TiGenix NV (TiGenix) and its subsidiaries TiGenix Inc. and TC CEF LLC. is a Belgium-based biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. The Company is exploiting the power of regenerative medicine for the development of durable treatments, validated through controlled clinical studies, for these indications. TiGenix is located in Leuven and was founded as a spin-off of the Catholic University of Leuven and the University of Ghent. TiGenix is developing a portfolio of products that addresses specific musculoskeletal problems. The lead indication among these is cartilage damage, which is a debilitating affliction severely affecting the mobility and functioning of patients. During the fiscal year ended December 31, 2009, the Company acquired Orthomimetics Ltd.

Fortimedix

Venture Round in 2004
Fortimedix B.V., founded in 1999 and based in Nuth, the Netherlands, specializes in the development and manufacturing of endovascular, coronary, and peripheral stents. As a global leader in stent technology, the company has established a strong presence in the medical device industry, focusing on innovation and continuous improvement. With full in-house capabilities for stent development and production, Fortimedix is dedicated to operational excellence. The company prioritizes research and development to advance its technology and meet the evolving needs of its customers and stakeholders.